Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical giant Nycomed announced that Daxas (roflumilast) aids in prevention of exacerbations in COPD patients of the ‘frequent exacerbator’ phenotype, as evident from new data analysis.
Subscribe to our email newsletter
Two one-year studies of over 1,500 roflumilast-treated patients with severe COPD, chronic bronchitis and a history of exacerbations were conducted.
Roflumilast treatment in patients who were frequent exacerbators showed reduced risk for those remaining in the frequent exacerbator state by 20% as compared to placebo
On the other hand, treatment with roflumilast among infrequent exacerbators over a year lowered the risk of becoming a frequent exacerbator by 23% as compared to placebo.
It was thus stated that COPD patients benefit by roflumilast treatment which shifts patients from the frequent to the more stable infrequent exacerbator state.
Daxas, which belongs to phosphodiesterase 4 (PDE4) inhibitors class of treatment has been approved for treating severe COPD associated with chronic bronchitis in countries, including the European Union, US and Canada.